medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Expanded Choices with Greater HIV Prevention Benefits: A
Mathematical Model of Long-Acting Injectable and Daily-Oral
Pre-Exposure Prophylaxis
Kevin M. Maloney,1* Robert A. Driggers,1 Supriya Sarkar,1 Emeli Anderson,1 Amyn A. Malik,1 Samuel M.
Jenness1
1

Department of Epidemiology, Emory University, Atlanta, GA

* Corresponding Author: Emory University, 1518 Clifton Road, Atlanta, GA 30322. kevin.maloney@emory.edu.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT
Objective: To assess the population impact of long-acting injectable pre-exposure prophylaxis (LAIPrEP) when available concurrently with daily oral (DO) PrEP among men who have sex with men (MSM).
Design: Dynamic network model of HIV transmission among MSM.
Methods: We calibrated our model to the current uptake of DO-PrEP (15% among indicated) and HIV
prevalence (25.3%) among MSM in the southeastern US. Parameters for LAI-PrEP pharmacokinetics and
efficacy were estimated from Phase IIa safety trials in human and macaque models. Primary analyses
explored varied conditions of PrEP uptake and proportion choosing LAI-PrEP given initiation. Secondary
analyses evaluated uncertainty in pharmacokinetic efficacy and in persistence to LAI-PrEP relative to DOPrEP.
Results: If 50% of MSM currently accessing DO-PrEP choose LAI-PrEP when it becomes available, an
additional 14.3% of infections could be averted over 10 years. If the availability of LAI-PrEP increased
overall uptake of PrEP to 50%, the expected infections averted would increase to 23.9%. The benefit of
LAI-PrEP was weakly sensitive to pharmacokinetics with 9.9% of infections averted even if LAI-PrEP
efficacy were half of current empirical estimates. The superiority of LAI-PrEP was strongly attributable to
better adherence and persistence with only 4.3% of infections averted if persistence were the same as
DO-PrEP.
Conclusions: LAI-PrEP availability is projected to decrease HIV incidence. However, increased benefits
depend upon improvements to adherence and persistence above current DO-PrEP levels. As LAI-PrEP
becomes available, uptake and persistence should be monitored to ensure optimal implementation.

KEY WORDS
Men who have sex with men; Mathematical model; Preexposure prophylaxis; Sexual network

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION
Men who have sex with men (MSM) remain at increased risk for HIV infection in the United
States, accounting two-thirds of all new infections in 2016 [1]. The introduction of pre-exposure
prophylaxis (PrEP), currently formulated as a once-daily oral tablet of emtricitabine and tenofovir
(FTC/TDF or FTC/TAF), has allowed some MSM to effectively reduce their risk of infection [2,
3]. However, implementation challenges undermine the potential for PrEP to reduce incidence
at the population level. For example, uptake of PrEP remains low [4-7]. The US Centers for
Disease Control and Prevention (CDC) estimate that 1.1 million US adults were behaviorally
indicated to use PrEP in 2017 [8], but only 100,000 accessed PrEP [4]. Efforts to increase PrEP
use may be undermined by poor persistence, resulting in early discontinuation among
individuals with ongoing HIV risk and low clinical retention [9-12]. Previous PrEP models have
predicted that current coverage levels are insufficient to reach many HIV prevention targets [13,
14]. Among MSM accessing PrEP, inadequate adherence further reduces its population-level
prevention benefits [10, 15].
Alternative PrEP products that are more acceptable and easier to use may address
these implementation challenges. There is precedent from other medications, such as
contraceptives, that increased choice results in greater uptake and more effective use [16].
Daily oral PrEP (DO-PrEP) is currently the only dosing strategy recommended by the CDC and
the US Food and Drug Administration [17]. However, alternative dosing regimens [18, 19] have
proven efficacious; novel formulations are in development, including long-acting injectable [20]
and topical formulations [21], implants, and other devices [22].
Cabotegravir is a strand-transfer integrase inhibitor currently in Phase III clinical trials for
PrEP [20]. When formulated as a long-acting injectable suspension, cabotegravir is maintained
with periodic dosing at 8-week intervals [20]. Long-acting injectable PrEP (LAI-PrEP) would
address adherence challenges associated with DO-PrEP because the burden of taking a pill

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

would be eliminated [15, 20]. Persistence may also increase with LAI-PrEP if the 8-week interval
between dosages is easier for individuals to manage and maintain (compared to daily dosage of
DO-PrEP). LAI-PrEP may be more acceptable for many unwilling or unable to take a daily tablet
[23-27]. Estimates of preference for LAI-PrEP range from 30% to 67% [23, 25, 27-30], but realworld selection of LAI-PrEP over DO-PrEP is unknown. Translating LAI-PrEP potential to realworld impact will ultimately depend on unknown uptake and persistence levels.
Because clinical trials of LAI-PrEP will only establish non-inferiority to DO-PrEP at the
individual level [31], modeling studies are an important tool to understand the mechanisms by
which LAI-PrEP may differ from DO-PrEP at the population level. A recent modeling study [32]
simulated the population impact of single formulations of PrEP by themselves. If LAI-PrEP was
allocated to 35% of MSM, HIV incidence would decrease by 44%; if DO-PrEP was used instead
of LAI-PrEP, incidence would decrease by 33%. Based on this, LAI-PrEP could improve upon
the population benefits of DO-PrEP, but the scenario of only one formulation available at a time
is unrealistic as having an option for both formulations is expected in practice. It was also
unclear from the model how realistic challenges to PrEP persistence will limit the population
impact of LAI-PrEP which, unlike DO-PrEP, provides continued but waning protection even after
discontinuation [20]. Since publication of this model, pharmacokinetic data from a Phase II
clinical trial of LAI-PrEP has become available [20], which can be used to specify model
parameters.
To estimate the potential population-level impact of LAI-PrEP, we used a sexual network
model of HIV transmission dynamics among MSM in the southeastern US. To understand how
concurrent availability of LAI-PrEP and DO-PrEP could maximize HIV prevention, we simulated
scenarios varying PrEP uptake and the proportion choosing LAI-PrEP compared to DO-PrEP.
Second, we conducted sensitivity analyses of the LAI-PrEP pharmacokinetic and efficacy
parameters to understand how uncertainty in these parameters could impact projections of

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

impact. Finally, to investigate the mechanisms by which LAI-PrEP could provide additional HIV
prevention benefits over an equivalent uptake level of DO-PrEP, we explored varying levels of
persistence among LAI-PrEP users.
METHODS
We used a mathematical model of HIV transmission dynamics among MSM in the Atlanta area
aged 18â€“40 years over a 10-year period. The model was simulated using EpiModel [33], a
software platform for simulating epidemics in sexual networks using temporal exponential
random graph models [34]. Our prior modeling work with this platform included a study of racial
disparities in the PrEP continuum of care, including initiation, adherence, and persistence [35].
In the present study, we build on this work by developing the model framework and
parameterization of LAI-PrEP and by incorporating the PrEP continuum of care to explore
differences between LAI-PrEP and DO-PrEP. Full methodological details can be found in the
Web Appendix.
Sexual Network Model of MSM. The model simulates one-off, casual, and main partnerships.
Partnership formation was determined stochastically by partnership type, age mixing, number of
existing partnerships, and sorting by receptive and insertive positioning. Relational dissolution
was modeled with a constant hazard based on the median duration for partnership type.
Behavior within sexual partnerships was determined stochastically. The probability of
HIV transmission was modified based on condom use [36], sexual positioning [37], circumcision
status of the insertive partner [38], and non-HIV sexually transmitted infections [39]. For MSM
with HIV, rates were assigned for diagnosis, initiation of antiretroviral therapy, and viral
suppression [40, 41]. Antiretroviral therapy decreased HIV viral loads, with a corresponding
decrease in the probability of HIV transmission [42, 43].

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

PrEP Uptake, Adherence, and Persistence. Uptake of PrEP was determined using a two-step
process. Parameters for LAI-PrEP and DO-PrEP are shown in Table 1. First, we specified the
probability of initiating PrEP of either kind. Second, we specified the probability of choosing LAIPrEP versus DO-PrEP. By simulating uptake using probabilities on two domains, we were able
to explore counterfactual scenarios in which the decisions interact. Eligibility to initiate PrEP was
determined based on CDC guidelines for DO-PrEP indications [13, 17]. For MSM using DOPrEP, we assigned a probability distribution for medication adherence corresponding to low (< 2
doses/week, 8.9%), medium (2â€“3 doses/week, 12.7%), and high adherence (â‰¥ 4 doses/week,
78.4%) [44], which modified the level of protection against HIV acquisition (hazard ratios: 0.69,
0.19, and 0.02, respectively) [15].
Based on CDC guidelines, behavioral indications were reassessed annually; if
indications had lapsed, PrEP would be discontinued for both DO-PrEP and LAI-PrEP [17]. We
also allowed for spontaneous discontinuation of DO-PrEP to occur based on an observational
study showing 57% of PrEP patients remained in care 6 months after initiation. We translated
this into a constant probability of discontinuation assuming a geometric distribution to calculate
the median time to event (224 days) [45]. It is unknown whether MSM using LAI-PrEP would
have the same rate of spontaneous discontinuation; the clinical burden is different than DOPrEP, and data from clinical trials are insufficient to predict persistence in the real-world.
Therefore, in the base model, we assumed that 21.5% of men would have poor LAI-PrEP
persistence (hereafter referred to as the â€œlow-persistentâ€ group), matching the total proportion of
DO-PrEP users with low or medium adherence. The rate of discontinuation among the lowpersistent matched the spontaneous discontinuation rate among those using DO-PrEP, while
the remainder of MSM using LAI-PrEP were not eligible for spontaneous discontinuation. We
varied the proportion low-persistent and the rate of discontinuation in counterfactual models.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Injectable PrEP Pharmacokinetics and Efficacy. Based on studies of nonhuman primates, the
target cabotegravir plasma concentration was set to 4-times the protein-adjusted 90% inhibitory
concentration (PA-IC90) [46-48]. A Phase IIa clinical trial showed that 600 mg intramuscular
injections at 8-week intervals were sufficient to maintain the target plasma concentration [20].
Prior to the maintenance phase, patients first complete a 4-week drug safety phase of oral
cabotegravir. Next, two 600 mg injections are administered with a 4-week interval, which is
necessary to initially achieve the target peak plasma concentration. For simplicity, we assumed
that men would achieve the target peak plasma concentration following the first injection and
without an initial oral safety phase.
Using data from the Phase IIa trial to model the pharmacokinetics of injectable
cabotegravir [20], we estimated the median peak plasma concentration (3.59 Âµg/ml) following
each injection after and including the second injection, as well as the rate of decay in
longitudinal follow-up. We then created a continuous half-life function (35 days) of drug
elimination based on these two parameters. Our model shows that plasma concentrations
above PA-IC90 and 4-times PA-IC90 are maintained for 22 and 12 weeks, respectively, with
limited drug still present 48 weeks after the final injection. Except where specified otherwise, we
held constant the base model parameters for LAI-PrEP for each of the experimental models.
A Phase III study to determine the efficacy of cabotegravir as LAI-PrEP is ongoing.
Thus, we used the results of a macaque study to model the relative reduction in the perexposure probability of HIV infection [46]. We used logistic regression to estimate the probability
of infection given the plasma concentration of cabotegravir at the time of exposure. We then
transformed the results to the human equivalent of the PA-IC90 to obtain a single parameter for
the relative reduction in infection probability given the plasma concentration of cabotegravir. Our
model predicts that LAI-PrEP is more than 99% efficacious at 4-times PA-IC90 (HR = 0.002).

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Base Model and Experimental Scenarios. The base model represents current uptake of DOPrEP, in which approximately 15% of indicated MSM in the southeastern US use PrEP [49, 50].
We calibrated the model to maintain a steady state prevalence of DO-PrEP use among
indicated MSM. To reach 15%, the probability of initiating PrEP given indications was set to
21%, while LAI-PrEP selection was set to 0%.
We examined a range of experimental scenarios. First, in our primary analysis, we
explored scenarios of overall PrEP uptake by simultaneously varying the probability of initiating
PrEP and the probability of selecting LAI-PrEP, each from 0% to 100%. The probability of
selecting LAI-PrEP was set to 50% for all secondary analyses, while the probability of initiating
PrEP was maintained at the base model value (21%). Second, to better understand the
pharmacological properties of LAI-PrEP, we varied the pharmacokinetic and efficacy
parameters. We varied the LAI-PrEP pharmacokinetics by simultaneously modifying the peak
plasma concentration after injection (1.5 to 6.5 Âµg/ml) and the half-life of drug elimination (15 to
60 days). Separately, we varied the efficacy of LAI-PrEP by scaling the per-exposure hazard
ratio for transmission (5%, 10%, 25%, and 50% increase or decrease in efficacy compared to
the base parameter). Finally, to understand how the effectiveness of LAI-PrEP could depend on
longitudinal use, we varied the proportion of MSM using LAI-PrEP that are considered lowpersistent and the rate of spontaneous discontinuation among the low-persistent. To do this, we
modified the median time using LAI-PrEP by 50% (112 days), 100% (224 days), 150% (336
days), and 200% (448 days) and calculated new spontaneous discontinuation rates. We
simultaneously varied the proportion considered low-persistent (21.5%, 25%, 50%, 75%, and
100%).
Calibration, Simulation, and Analysis. The network was initialized with 10,000 MSM and
calibrated to the observed HIV prevalence (25.3%) at baseline in a cohort of MSM in Atlanta,
Georgia [51]. Each model scenario was simulated over 10 years and for 250 times. The

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

outcomes reported were HIV prevalence and incidence per 100 person-years at risk at the end
of 10 years, and the percent of infections averted (PIA). The PIA was calculated by comparing
the cumulative incidence in each experimental scenario to the base model. We summarized the
results using the median values of all simulations and 95% simulation intervals (SI).
RESULTS
In the base model scenario, 15.1% of indicated MSM are using DO-PrEP (0% LAIPrEP). At the end of the 10-year simulation, the HIV incidence was 2.77 (95% SI: 2.27, 3.23)
per 100 person-years and prevalence was 21.8% (95% SI: 20.4, 23.4). Figure 1 shows that
increasing both the probability of initiating PrEP and the probability of selecting LAI-PrEP would
result in fewer infections over 10 years, compared to the base model scenario. The benefit of
introducing LAI-PrEP is maximized in scenarios where both probabilities increase. Substantial
improvements, however, would still be realized at lower proportions of MSM initiating PrEP and
selecting LAI-PrEP.
Table 2 shows that increasing both the initiation and the LAI-PrEP selection probabilities
will increase the proportion of indicated MSM using PrEP of any kind, which in turn causes HIV
incidence to decline. While keeping the model limited to DO-PrEP, increasing the probability of
initiating PrEP from 21% to 50% resulted in twice as many indicated MSM using DO-PrEP
(15.1% to 30%, respectively) and 13.8 PIA (95% SI: 3.3, 22.0). Alternatively, total PrEP use
increased to 30.5% when the probability of selecting LAI-PrEP was increased to 50%, even
though the probability of initiating PrEP was held constant at 21%, causing 14.3 PIA (95% SI:
5.4, 22.6). Due to similar overall PrEP use, these two scenarios yielded comparable values for
PIA despite different proportions using LAI-PrEP. If 100% of the MSM accessing PrEP were to
choose LAI-PrEP and initiation remained at 21%, PrEP use would further increase to 41.0%
among indicated MSM with 23.9 PIA (95% SI: 15.3, 31.0). Finally, if the probability of initiating

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

PrEP and the proportion choosing LAI-PrEP were each set to 50%, then the population impact
would increase to 34.3 PIA (95% SI: 27.5, 41.2).
Figure 2 shows that the underlying estimates for LAI-PrEP pharmacokinetics are robust
to uncertain parameter values. If the peak plasma concentration were reduced to 2 Âµg/ml and
the half-life were reduced to 15 days (an extreme scenario, well below the a priori clinical trial
targets), the impact on the population benefit of LAI-PrEP would be small. If the parameters are
modified within a smaller range around our estimates, the impact is negligible. Similarly, Table 3
shows that the population impact of LAI-PrEP would decrease only modestly if our estimate of
the drug efficacy were overestimated. For example, a 50% decrease in LAI-PrEP efficacy still
prevented 9.9% (95% SI: 0.2, 19.0) of infections, compared to 14.3 PIA (95% SI: 5.4, 22.6) if the
base model parameter for efficacy is used.
Table 4 shows the effect of varying longitudinal persistence for LAI-PrEP. As persistence
decreases, the prevalence of LAI-PrEP use among indicated MSM also decreases. When the
percent low-persistent increased from 21% to 100%, the prevalence of LAI-PrEP use decreased
from 24.1% to 8.2%. This caused the PIA to also decline from 14.3% (95% SI: 5.4, 22.6) to
4.3% (95% SI: -4.8, 14.4). Modifying the rate of discontinuation among the low-persistent had a
modest impact on the overall prevalence of LAI-PrEP if the percent low-persisent was
maintained at the base level (21.5%). If the median time to discontinuation was reduced by half
(from 224 days to 112 days) the prevalence of total LAI-PrEP use would only decrease to 23.4%
(from 24.1%). However, if the percent low-persistent also increased to 100%, the decreased
time to discontinuation would have a greater effect, with only 5.1% of indicated MSM using LAIPrEP and 2.1 PIA (95% SI: -8.2, 11.2). In scenarios with 100% of MSM using LAI-PrEP
considered low-persistent, doubling the median time to discontinuation (from 224 days to 448
days) was insufficient to compensate for the increased proportion experiencing spontaneous
discontinuation.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

DISCUSSION
In this study, we demonstrated that the introduction of LAI-PrEP as a formulation concurrently
available to DO-PrEP could substantially reduce HIV incidence among MSM compared to
offering only DO-PrEP. The largest improvements to HIV prevention would occur when the
availability of LAI-PrEP coincides with overall increased PrEP initiation. However, LAI-PrEP
could provide important gains in HIV prevention, even if overall PrEP uptake remains at current
levels. This is primarily due to improvements in adherence and persistence expected with LAIPrEP. To our knowledge, this is the first modeling study to predict the population impact of LAIPrEP when available concurrently with DO-PrEP.
Low uptake has been a limiting factor to the population benefit of DO-PrEP since it first
became available [4-6]. We designed our model to explore PrEP uptake on two domains, overall
uptake of PrEP and proportion using LAI-PrEP, in order to represent a range of possible
scenarios. Similar to other studies [13, 14], we found that large scale reductions in HIV
incidence will require greater uptake of PrEP among MSM than has currently been observed in
the US [4-6]. Our model shows that this can be achieved if the availability of LAI-PrEP increases
the proportion of at-risk individuals accessing PrEP; and that further reductions in HIV incidence
could occur if those currently accessing DO-PrEP transition to LAI-PrEP.
The benefit of LAI-PrEP compared to DO-PrEP at fixed levels of PrEP uptake is
contingent upon increased persistence which results in longer sustained person-time using
PrEP in our model. Partial protection provided during the long metabolic half-life after
discontinuation further increases the person-time of protection in the population. Our finding is in
direct contrast to the earlier LAI-PrEP modeling study, which reported greater population impact
of LAI-PrEP as persistence decreased [32]. In their model, PrEP was allocated to maintain a
constant prevalence of active users in the population, so that a new individual was forced to
replace each discontinuation. As a result, the total person-time of LAI-PrEP would

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

counterintuitively increase in scenarios with lower persistence, because the number of
individuals with partial protection increased. We found this model assumption unrealistic, and
therefore its population impact implausible. In our model, the two components of PrEP
prevalence (initiation and persistence) were disentangled in order to evaluate the individual
contribution of each factor. We were therefore able to vary LAI-PrEP persistence without
artificially inflating the person-time of LAI-PrEP use, thereby isolating the effects of initiation and
persistence. Our model shows that, in order to achieve sufficient coverage of PrEP use in the
population, persistence must be optimized for DO-PrEP and LAI-PrEP.
Our model represents an optimistic scenario of increased persistence among those
using LAI-PrEP compared to DO-PrEP, but persistence will likely remain a challenge for all
persons accessing PrEP. The reasons for discontinuation of DO-PrEP in the real-world include
decreased HIV risk perception, non-adherence to the clinical protocol for PrEP, insurance
barriers and experiencing side-effects [9, 52]. We assumed that persistence would improve with
LAI-PrEP, in part because the 8-week intervals between dosing would encompass periods of
temporary decreased risk in which some individuals would otherwise discontinue DO-PrEP. We
also assumed that the lack of daily adherence would decrease fatigue, making it more likely that
individuals would be motivated to maintain the protocol. This assumption may be unrealistic
since more frequent clinical care visits (i.e., six annual visits for LAI-PrEP compared to four for
DO-PrEP) may be more burdensome for some. However, the differing clinical procedure of LAIPrEP may attract individuals whom are not willing to use DO-PrEP. Implementation strategies
for LAI-PrEP should anticipate challenges to persistence and include support programs to help
patients evaluate risk and ensure longitudinal persistence when appropriate.
Limitations. Our model has a number of important limitations. The first is uncertainty of the LAIPrEP parameters, since Phase III clinical trials are ongoing. Our model parameters may be
misspecified which would cause our primary results to be biased. However, we tested a range

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

of plausible parameters for LAI-PrEP pharmacokinetics and efficacy, which had only a small
effect on the model results. Our model is also a simplification of the protocol for LAI-PrEP used
in the ongoing Phase III clinical trial. Specifically, we did not include the 4-week oral dosing
phase of cabotegravir that is used to ensure safety. We also assumed that the peak plasma
concentration for cabotegravir would be achieved after a single intramuscular dose, instead of
the two initial doses at a 4-week interval. Similarly, we did not model an oral ramp-down phase
for individuals discontinuing LAI-PrEP under the supervision of their clinician (opposed to
spontaneous discontinuation). This later phase of LAI-PrEP is used to prevent infection during
the waning tail of LAI-PrEP protection. Increased complexity and clinical burden of the protocol
will likely result in lower persistence, decreasing the person-time of LAI-PrEP coverage in the
population. Finally, we did not model resistance to cabotegravir among individuals that acquire
HIV infection following discontinuation of LAI-PrEP, while the drug remains present but provides
only partial protection. This phenomenon presents a new challenge compared to DO-PrEP,
which rapidly metabolizes after discontinuation. However, resistance was estimated to be rare in
the earlier model of cabotegravir-based LAI-PrEP [32].
Conclusions. LAI-PrEP has the potential to further transform the HIV prevention paradigm,
building on the progress since DO-PrEP became available. The superiority of LAI-PrEP in our
model is tied to improvements in adherence and persistence rather than pharmacological
efficacy. The maximal benefit of LAI-PrEP will be realized only if uptake is robust and individuals
are persistent following initiation. These are not trivial challenges, but lessons learned from the
implementation of DO-PrEP can inform strong public health programs to promote and support
the use of LAI-PrEP among indicated persons. As LAI-PrEP becomes available, uptake and
persistence should be closely monitored along with DO-PrEP to identify opportunities to
optimize implementation of each.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ACKNOWLEDGEMENTS
This work was supported by National Institutes of Health grants R21 MH112449, R01 AI138783,
and P30 AI050409 (Emory University Center for AIDS Research).

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence
in the United States, 2010â€“2016. In: HIV Surveillance Supplemental Report; 2019.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure
chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;
363(27):2587-2599.
3. Spinner CD, Brunetta J, Shalit P, Prins M, Cespedes M, Mathias A, et al. DISCOVER study
for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer
sustained duration of HIV protection compared with F/TDF. In: 10th IAS Conference on HIV
Science. Mexico City, Mexico; 2019.
4. Sullivan PS, Giler RM, Mouhanna F, Pembleton ES, Guest JL, Jones J, et al. Trends in the
use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis
against HIV infection, United States, 2012-2017. Ann Epidemiol 2018; 28(12):833-840.
5. Finlayson T, Cha S, Xia M, Trujillo L, Denson D, Prejean J, et al. Changes in HIV
Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men - 20
Urban Areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep 2019; 68(27):597-603.
6. Kamitani E, Wichser ME, Adegbite AH, Mullins MM, Johnson WD, Crouch PC, et al.
Increasing prevalence of self-reported HIV preexposure prophylaxis use in published
surveys: a systematic review and meta-analysis. AIDS 2018; 32(17):2633-2635.
7. Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV PreExposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United
States. J Acquir Immune Defic Syndr 2017; 74(3):285-292.
8. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV preexposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United
States, 2015. Ann Epidemiol 2018; 28(12):850-857 e859.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

9. Krakower D, Maloney KM, Powell VE, Levine K, Grasso C, Melbourne K, et al. Patterns and
clinical consequences of discontinuing HIV preexposure prophylaxis during primary
care. J Int AIDS Soc 2019; 22(2):e25250.
10. Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al.
Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System:
Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr 2016;
73(5):540-546.
11. Marcus JL, Hurley LB, Nguyen DP, Silverberg MJ, Volk JE. Redefining Human
Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures. Clin Infect Dis 2017;
65(10):1768-1769.
12. Scott HM, Spinelli M, Vittinghoff E, Morehead-Gee A, Hirozawa A, James C, et al.
Racial/ethnic and HIV risk category disparities in preexposure prophylaxis
discontinuation among patients in publicly funded primary care clinics. AIDS 2019;
33(14):2189-2195.
13. Jenness SM, Goodreau SM, Rosenberg E, Beylerian EN, Hoover KW, Smith DK, et al.
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for
Men Who Have Sex With Men in the United States. J Infect Dis 2016; 214(12):1800-1807.
14. Sullivan PS, Carballo-Dieguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, et al.
Successes and challenges of HIV prevention in men who have sex with men. Lancet 2012;
380(9839):388-399.
15. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender
women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14(9):820-829.
16. Gray AL, Smit JA, Manzini N, Beksinska M. Systematic review of contraceptive
medicines: "Does choice make a difference?". In: WHO RHRU; 2006.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

17. Centers for Disease Control and Prevention. Preexposure prophylaxis for the
prevention of HIV infection in the United States - 2017 update: a clinical practice
guideline. In; 2018.
18. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand
Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015;
373(23):2237-2246.
19. Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and
effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who
have sex with men: an observational cohort study. Lancet HIV 2017; 4(9):e402-e410.
20. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, et al. Safety, tolerability,
and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected
individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med 2018;
15(11):e1002690.
21. Baeten J. Topical and on-demand PrEP. In: 10th IAS Conference on HIV Science. Mexico
City, Mexico: International AIDS Society; 2019.
22. Flexner CW. Implants and transdermal drug delivery systems for HIV prevention. In:
10th IAS Conference on HIV Science. Mexico City, Mexico: International AIDS Society; 2019.
23. Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and Preferences for Oral
and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of
Gay and Bisexual Men in the U.S. AIDS Behav 2016; 20(7):1390-1399.
24. Biello K, Coffey-Esquivel J, Hosek S, Belzer M, Sullivan P, Mimiaga M, et al. Development
of a mobile-based application to increase uptake of HIV testing among young US men
who have sex with men. J Int Aids Soc 2016; 19.
25. Greene GJ, Swann G, Fought AJ, Carballo-Dieguez A, Hope TJ, Kiser PF, et al.
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. AIDS Behav 2017;
21(5):1336-1349.
26. Biello KB, Hosek S, Drucker MT, Belzer M, Mimiaga MJ, Marrow E, et al. Preferences for
Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men
Who Have Sex with Men. Arch Sex Behav 2018; 47(7):2101-2107.
27. Meyers K, Wu Y, Brill A, Sandfort T, Golub SA. To switch or not to switch: Intentions to
switch to injectable PrEP among gay and bisexual men with at least twelve months oral
PrEP experience. PLoS One 2018; 13(7):e0200296.
28. Levy ME, Patrick R, Gamble J, Rawls A, Opoku J, Magnus M, et al. Willingness of
community-recruited men who have sex with men in Washington, DC to use long-acting
injectable HIV pre-exposure prophylaxis. PLoS One 2017; 12(8):e0183521.
29. Biello KB, Mimiaga MJ, Santostefano CM, Novak DS, Mayer KH. MSM at Highest Risk for
HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral
PrEP Compared to Daily, Oral Medication. AIDS Behav 2018; 22(4):1158-1164.
30. John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will Gay and Bisexual Men
Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP
Should It Become Available? AIDS Behav 2018; 22(4):1184-1189.
31. Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Pre-exposure prophylaxis
2.0: new drugs and technologies in the pipeline. Lancet HIV 2019; 6(11):e788-e799.
32. Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA, et al. Potential
effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in
men who have sex with men: a modelling study. Lancet HIV 2018; 5(9):e498-e505.
33. Jenness SM, Goodreau SM, Morris M. EpiModel: An R Package for Mathematical
Modeling of Infectious Disease over Networks. J Stat Softw 2018; 84.
34. Krivitsky PN, Handcock MS. A Separable Model for Dynamic Networks. J R Stat Soc
Series B Stat Methodol 2014; 76(1):29-46.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

35. Jenness SM, Maloney KM, Smith DK, Hoover KW, Goodreau SM, Rosenberg ES, et al.
Addressing Gaps in HIV Preexposure Prophylaxis Care to Reduce Racial Disparities in
HIV Incidence in the United States. Am J Epidemiol 2018.
36. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by
consistency of use among men who have sex with men in the United States. J Acquir
Immune Defic Syndr 2015; 68(3):337-344.
37. Goodreau SM, Carnegie NB, Vittinghoff E, Lama JR, Sanchez J, Grinsztejn B, et al. What
drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS
One 2012; 7(11):e50522.
38. Wiysonge CS, Kongnyuy EJ, Shey M, Muula AS, Navti OB, Akl EA, et al. Male
circumcision for prevention of homosexual acquisition of HIV in men. Cochrane Database
Syst Rev 2011; (6):CD007496.
39. Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of
Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure
Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. Clin Infect Dis 2017;
65(5):712-718.
40. Beer L, Mattson CL, Bradley H, Shouse RL, Medical Monitoring P. Trends in ART
Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the
United States, 2009-2013. J Acquir Immune Defic Syndr 2017; 76(1):e1-e6.
41. Beer L, Oster AM, Mattson CL, Skarbinski J, Medical Monitoring P. Disparities in HIV
transmission risk among HIV-infected black and white men who have sex with men,
United States, 2009. AIDS 2014; 28(1):105-114.
42. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al.
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant
couples. J Infect Dis 2012; 205(3):358-365.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

43. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;
365(6):493-505.
44. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al.
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and CommunityBased Sexual Health Services. JAMA Intern Med 2016; 176(1):75-84.
45. Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al.
Retention in care outcomes for HIV pre-exposure prophylaxis implementation
programmes among men who have sex with men in three US cities. J Int AIDS Soc 2016;
19(1):20903.
46. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase
inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
Science 2014; 343(6175):1151-1154.
47. Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, et al. A
long-acting integrase inhibitor protects female macaques from repeated high-dose
intravaginal SHIV challenge. Sci Transl Med 2015; 7(270):270ra274.
48. Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, Garcia-Lerma JG, et al. The longacting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV
challenge. Sci Transl Med 2015; 7(270):270ra275.
49. Kelley CF, Kahle E, Siegler A, Sanchez T, Del Rio C, Sullivan PS, et al. Applying a PrEP
Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis
2015; 61(10):1590-1597.
50. Goedel WC, Halkitis PN, Greene RE, Hickson DA, Duncan DT. HIV Risk Behaviors,
Perceptions, and Testing and Preexposure Prophylaxis (PrEP) Awareness/Use in GrindrUsing Men Who Have Sex With Men in Atlanta, Georgia. J Assoc Nurses AIDS Care 2016;
27(2):133-142.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

51. Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, et al. Explaining
racial disparities in HIV incidence in black and white men who have sex with men in
Atlanta, GA: a prospective observational cohort study. Ann Epidemiol 2015; 25(6):445-454.
52. Lankowski AJ, Bien-Gund CH, Patel VV, Felsen UR, Silvera R, Blackstock OJ. PrEP in the
Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort. AIDS Behav 2019;
23(7):1797-1802.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

TABLES
Table 1. Pre-exposure prophylaxis parameters in all models and values varied in experimental
scenarios.
Parameter

Base Model

Experimental
Scenarios

Reference

Initiation
Prevalence of PrEP use given indication

15.1%

Varies

Probability of initiating PrEP

21.0%

0 â€“ 100%

[49, 50]

[23, 25, 27-

Probability of selecting LAI-PrEP

30]

Primary Analysis

0%

0 â€“ 100%

Secondary Analyses

0%

50%

DO-PrEP
Adherence level, % of DO-PrEP users

[44]

Low (< 2 doses/week)

8.9%

---

Medium (2-3 doses/week)

12.7%

---

High (4+ doses/week)

78.4%

---

Efficacy, per-exposure hazard-ratio

[15]

Low adherence

0.69

---

Medium adherence

0.19

---

High adherence

0.02

---

224 days

---

[45]

3.59 Âµg/ml

1.5 â€“ 6.5 Âµg/ml

[20]

35 days

15 â€“ 60 days

[20]

Varies

---

Spontaneous discontinuation rate,
median time
LAI-PrEP
Peak plasma concentration ( )
Half-life ( /)
Days since last injection ()
Plasma concentration (  )
Efficacy, per-exposure hazard-ratio

1
2

  




 /

 

---

[20]

Â± 5% â€“ 50%

Beta ()

-9.06

---

[46]

Hazard-ratio at 4 x PA-IC90

0.002

---

[46]

21.5%

0 â€“ 100%

224 days

112 â€“ 448 days

Proportion low-persistent
Spontaneous discontinuation rate among
low-persistent, median time

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Proportion of indicated MSM using daily-oral or long-acting injectable pre-exposure prophylaxis, HIV prevalence, HIV
incidence per 100 person-years at risk, and percent of infections averted over 10 years compared to the base model scenario,
across varying PrEP-initiation and formulation-selection probabilities.
% DO-

% LAI-

HIV prevalence

HIV incidence4

PIA5

PrEP1

PrEP2

(95% SI3)

(95% SI3)

(95% SI3)

0%

7.7%

0.0%

23.4% (21.8, 24.9)

3.02 (2.52, 3.65)

-6.4% (-18.7, 3.5)

25%

5.5%

7.1%

22.4% (20.9, 24.1)

2.77 (2.30, 3.29)

-1.8% (-13.8, 7.2)

50%

3.5%

13.5%

21.7% (20.3, 23.2)

2.57 (2.15, 3.12)

1.6% (-9.7, 12.4)

75%

1.7%

19.3%

21.0% (19.7, 22.6)

2.42 (1.97, 2.86)

5.7% (-4.1, 14.9)

100%

0.0%

24.6%

20.5% (19.1, 21.9)

2.27 (1.84, 2.74)

8.7% (-0.3, 17.5)

0%

15.1%

0.0%

21.8% (20.4, 23.4)

2.77 (2.27, 3.23)

Base Model

25%

10.3%

13.2%

20.4% (19.0, 21.9)

2.36 (1.93, 2.79)

7.9% (-2.3, 16.8)

50%

6.4%

24.1%

19.2% (17.8, 20.6)

2.08 (1.71, 2.44)

14.3% (5.4, 22.6)

75%

3.0%

33.1%

18.3% (16.9, 19.5)

1.87 (1.51, 2.29)

19.5% (10.5, 26.9)

100%

0.0%

41.0%

17.5% (16.3, 18.8)

1.70 (1.34, 2.07)

23.9% (15.3, 31.0)

0%

20.3%

0.0%

20.9% (19.3, 22.2)

2.57 (2.13, 3.04)

4.1% (-5.2, 14.3)

25%

13.5%

17.2%

19.0% (17.6, 20.4)

2.10 (1.72, 2.52)

14.5% (5.9, 22.9)

50%

8.2%

30.6%

17.7% (16.3, 19.1)

1.77 (1.44, 2.18)

22.1% (13.1, 30.2)

75%

3.8%

41.2%

16.6% (15.5, 17.8)

1.56 (1.26, 1.92)

27.7% (20.0, 35.2)

100%

0.0%

50.1%

15.8% (14.7, 17.0)

1.42 (1.15, 1.74)

32.1% (25.1, 39.1)

0%

25.4%

0.0%

19.8% (18.3, 21.4)

2.41 (1.98, 2.85)

9.2% (-0.5, 18.8)

25%

16.6%

21.0%

17.7% (16.3, 18.9)

1.84 (1.51, 2.25)

21.0% (12.4, 29.8)

50%

9.9%

36.4%

16.2% (15.0, 17.4)

1.55 (1.23, 1.85)

28.9% (21.4, 36.5)

75%

4.5%

48.1%

15.2% (14.1, 16.3)

1.34 (1.07, 1.67)

34.8% (27.5, 41.6)

100%

0.0%

57.7%

14.4% (13.4, 15.5)

1.20 (0.98, 1.51)

38.9% (31.9, 45.9)

0%

30.0%

0.0%

18.9% (17.5, 20.4)

2.25 (1.84, 2.68)

13.8% (3.3, 22.0)

25%

19.2%

24.1%

16.6% (15.3, 17.8)

1.66 (1.34, 2.03)

26.3% (18.0, 33.3)

50%

11.3%

40.9%

15.0% (13.9, 16.2)

1.35 (1.08, 1.70)

34.3% (27.5, 41.2)

75%

5.1%

53.5%

14.0% (12.9, 15.1)

1.17 (0.92, 1.45)

40.4% (34.2, 46.4)

100%

0.0%

63.5%

13.3% (12.2, 14.2)

1.05 (0.80, 1.28)

44.7% (37.7, 50.6)

Probability of initiating PrEP = 10%
Probability of
6

choosing LAI-PrEP

Probability of initiating PrEP = 21%
Probability of
6

choosing LAI-PrEP

Probability of initiating PrEP = 30%
Probability of
6

choosing LAI-PrEP

Probability of initiating PrEP = 40%
Probability of
6

choosing LAI-PrEP

Probability of initiating PrEP = 50%
Probability of
6

choosing LAI-PrEP

1

Proportion using daily-oral pre-exposure prophylaxis among HIV-negative MSM with a behavioral indication for PrEP.

2

Proportion using long-acting injectable pre-exposure prophylaxis among HIV-negative MSM with a behavioral indication for

PrEP. 3Simulation Interval. 4Incidence per 100 person-years at risk. 5Percent of infections averted over 10 years compared to
the base model scenario. 6Versus choosing DO-PrEP.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. HIV prevalence, HIV incidence (per 100 person-years at risk), and
percent of infections averted over 10 years compared to the base model scenario,
across varying relative changes in long-acting injectable pre-exposure prophylaxis
efficacy.
HIV prevalence

HIV incidence2

PIA3

(95% SI1)

(95% SI1)

(95% SI1)

Experimental scenarios
50% Decrease

20.0% (18.5, 21.3)

2.32 (1.89, 2.76)

9.9% (0.2, 19.0)

25% Decrease

19.7% (18.2, 21.0)

2.22 (1.82, 2.65)

11.9% (2.8, 21.1)

10% Decrease

19.4% (18.1, 20.9)

2.14 (1.71, 2.56)

13.4% (4.5, 21.6)

5% Decrease

19.4% (18.0, 21.0)

2.11 (1.69, 2.58)

13.6% (4.1, 22.1)

Base Model

21.8% (20.4, 23.4)

2.77 (2.27, 3.23)

14.3% (5.4, 22.6)

5% Increase

19.2% (17.9, 20.6)

2.05 (1.65, 2.49)

14.7% (4.8, 22.5)

10% Increase

19.0% (17.8, 20.4)

2.00 (1.66, 2.45)

15.4% (6.6, 23.9)

25% Increase

18.9% (17.7, 20.2)

1.96 (1.62, 2.37)

16.1% (7.7, 23.8)

50% Increase

18.6% (17.1, 19.9)

1.89 (1.49, 2.29)

1

2

17.7% (8.5, 26.6)
3

Simulation Interval. Incidence per 100 person-years at risk. Percent of

infections averted over 10 years compared to the base model scenario.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 4. Proportion of indicated MSM using daily-oral pre-exposure prophylaxis or long-acting injectable pre-exposure
prophylaxis, HIV prevalence, HIV incidence per 100 person-years at risk, and percent of infections averted over 10 years,
compared to the base model scenario, across varying spontaneous discontinuation rates and proportion of MSM using LAIPrEP considered low-persistent.
% DO-

% LAI-

HIV prevalence

HIV incidence5

PIA6

PrEP2

PrEP3

(95% SI4)

(95% SI4)

(95% SI4)

---

15.1%

0%

21.8% (20.4, 23.4)

2.77 (2.27, 3.23)

Base model

0%

6.1%

28.3%

18.8% (17.5, 20.3)

1.97 (1.62, 2.38)

16.6% (7.5, 24.6)

% LP1
Base model
Scenario

Median time using LAI-PrEP before discontinuation = 112 days
21.5%

6.4%

23.4%

19.3% (17.9, 20.8)

2.08 (1.72, 2.57)

13.5% (4.2, 22.1)

25%

6.5%

22.5%

19.4% (18.1, 20.8)

2.12 (1.76, 2.58)

13.2% (4.0, 21.9)

50%

6.9%

16.8%

20.1% (18.7, 21.5)

2.28 (1.87, 2.75)

9.3% (-0.1, 19.4)

75%

7.4%

11.0%

20.7% (19.2, 22.4)

2.45 (2.00, 2.97)

5.8% (-4.5, 15.5)

100%

7.8%

5.1%

21.5% (19.9, 23.0)

2.69 (2.22, 3.17)

2.1% (-8.2, 11.2)

Median time using LAI-PrEP before discontinuation = 224 days
21.5%

6.4%

24.1%

19.2% (17.8, 20.6)

2.08 (1.71, 2.44)

14.3% (5.4, 22.6)

25%

6.4%

23.3%

19.3% (18.0, 20.6)

2.09 (1.70, 2.50)

13.6% (4.5, 22.0)

50%

6.8%

18.3%

19.8% (18.5, 21.3)

2.24 (1.84, 2.73)

10.8% (0.5, 20.7)

75%

7.3%

13.3%

20.5% (19.2, 21.9)

2.39 (2.01, 2.86)

7.2% (-2.9, 16.0)

100%

7.6%

8.2%

21.0% (19.5, 22.6)

2.57 (2.10, 3.05)

4.3% (-4.8, 14.4)

Median time using LAI-PrEP before discontinuation = 336 days
21.5%

6.4%

24.5%

19.2% (17.8, 20.5)

2.04 (1.65, 2.49)

14.8% (5.6, 23.6)

25%

6.4%

24.0%

19.2% (18.0, 20.8)

2.08 (1.74, 2.54)

14.4% (4.7, 23.2)

50%

6.7%

19.5%

19.8% (18.4, 21.2)

2.21 (1.82, 2.59)

11.6% (1.7, 20.8)

75%

7.1%

15.1%

20.3% (18.8, 21.7)

2.36 (1.97, 2.80)

8.9% (-1.0, 17.6)

100%

7.4%

10.7%

20.8% (19.4, 22.1)

2.50 (2.06, 2.90)

6.3% (-4.3, 15.1)

Median time using LAI-PrEP before discontinuation = 448 days

1

21.5%

6.3%

25.0%

19.1% (17.7, 20.5)

2.04 (1.66, 2.48)

14.9% (5.1, 23.1)

25%

6.4%

24.5%

19.2% (18.0, 20.7)

2.09 (1.69, 2.49)

14.1% (4.9, 23.4)

50%

6.7%

20.5%

19.6% (18.2, 21.0)

2.17 (1.82, 2.61)

12.1% (2.4, 21.5)

75%

7.0%

16.6%

20.1% (18.7, 21.7)

2.32 (1.88, 2.81)

9.6% (-0.1, 19.0)

100%

7.3%

12.5%

20.5% (18.8, 21.9)

2.42 (2.01, 2.93)

7.4% (-2.3, 17.1)

2

Proportion low-persistent among those using long-acting injectable PrEP. Proportion using daily-oral pre-exposure

prophylaxis among HIV-negative MSM with a behavioral indication for PrEP. 3Proportion using long-acting injectable preexposure prophylaxis among HIV-negative MSM with a behavioral indication for PrEP. 4Simulation Interval. 5Incidence per
100 person-years at risk. 6Percent of infections averted over 10 years compared to the base model scenario.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURES
Figure 1. Percent of infections averted (PIA) over 10 years, compared to the base model
scenario of 21% probability of initiating pre-exposure prophylaxis (PrEP) among behaviorally
indicated MSM and 0% choosing long-acting injectable pre-exposure prophylaxis (LAI-PrEP),
across varying PrEP-initiation and formulation-selection probabilities (LAI-PrEP versus daily-oral
al
PrEP). Dashed line indicates 21% probability of initiating PrEP (0% LAI-PrEP) used in the base
model.

medRxiv preprint doi: https://doi.org/10.1101/19012443; this version posted November 22, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Percent of infections averted (PIA) over 10 years, compared to the base model
scenario of 21% probability of initiating pre-exposure prophylaxis (PrEP) among behaviorally
indicated MSM and 0% choosing long-acting injectable pre-exposure prophylaxis (LAI-PrEP),
after LAI-PrEP is introduced (50% LAI-PrEP) across varying parameters for LAI-PrEP
pharmacokinetics. Dashed lines indicate peak plasma concentration (3.59 Âµg/ml) and half-life (5
weeks) used in the base model.

Probability of choosing LAIâˆ’PrEP

1.00

0.75

PIA
50%
40%
30%
20%
10%
0%
âˆ’10%

0.50

0.25

0.00
0.00

0.25

0.50

0.75

Probability of Initiating PrEP

1.00

Halfâˆ’life (Weeks)

8

PIA
16%
15%
14%
13%
12%
11%
10%
9%

6

4

2
2

3

4

5

Peak Plasma Concentration (ug/ml)

6

